Experience

Tempus Announces Upsized $650 Million Convertible Senior Notes Offering

June 30, 2025

Cooley advised Tempus AI (Nasdaq: TEM), a technology company advancing precision medicine and patient care through artificial intelligence, on its offering of $650 million aggregate principal amount of 0.75% convertible senior notes due 2030 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Read more

Related contacts

Christina T. Roupas
Partner in Charge – Chicago, Chicago
Jason Savich
Partner, San Francisco
Mischi a Marca
Partner, San Francisco
Xander Lee
Partner, Santa Monica
Eileen Marshall
Partner, Washington, DC
Addison Pierce
Partner, Chicago
Timothy Shapiro
Partner, Palo Alto
Courtney M.W. Tygesson
Partner, Chicago
Francis Wheeler
Senior Counsel, Colorado
Shimeng Cheng
Special Counsel, San Francisco
Mateus Kaba Aboud
Associate, Chicago
Yoni Horn
Associate, Santa Monica
Rick Jantz
Associate, Santa Monica
Pengli Li
Associate, Boston
Xueqing Li
Associate, San Francisco
Madison (JJ) Meng
Associate, San Francisco
Samuel Paullin
Associate, Chicago
Stevie Yu
Associate, New York

Related Practices & Industries

PhaseBio Chapter 11 Wind-Down Plan Goes Effective

June 26, 2024

The Chapter 11 plan of PhaseBio Pharmaceuticals, a long-standing Cooley life sciences client, has gone effective following the court’s confirmation of the Chapter 11 plan on June 26, 2024. The plan provides for a global settlement with the official committee of unsecured creditors and a settlement with PhaseBio’s former co-development partner. The Chapter 11 bankruptcy case in the US Bankruptcy Court for the District of Delaware was handled by a multioffice, cross-disciplinary Cooley team.

Related contacts

Jeremiah P. Ledwidge
Associate, New York
Robert Eisenbach
Of Counsel, San Francisco
Olya Antle
Associate, Washington, DC
Cullen Drescher Speckhart
Partner, Washington, DC
Philip Bowman
Partner, New York
Victoria R. Pasculli
Associate, New York
Daniel Lockaby
Associate, New York
Dannielle Antone
Associate, San Francisco
Aaron Binstock
Partner, Washington, DC
Amanda Lindner
Associate, New York
Madison Jones
Partner, Washington, DC
Timothy Shapiro
Partner, Palo Alto
Grigor Lynch
Associate, Colorado
Christian Plaza
Partner, Reston
Joe Sandys
Special Counsel, London
Aaron Pomeroy
Partner, Colorado
David Brinton
Associate, Washington, DC
Paul Springer
Associate, New York
Erika Freeman
Associate, New York
Michael Klein
Partner, New York
Daniel Knauss
Partner, Palo Alto
Pengli Li
Associate, Boston
Marya Postner
Partner, Palo Alto
Leo Metz
Associate
Dr. Michael Tuscan
Partner, Washington, DC
Allison Wettstein O’Neill
Associate, San Diego

Related Practices & Industries

Core Scientific to Combine With SPAC Power & Digital Infrastructure Acquisition Corp.

August 18, 2021

Cooley advised Core Scientific, a carbon-neutral vertically integrated blockchain infrastructure and mining company, on its merger agreement with special purpose acquisition company (SPAC) Power & Digital Infrastructure Acquisition Corp. The transaction values the combined company, which will be called Core Scientific Inc. and listed on the Nasdaq, at an implied pro forma fully diluted enterprise value of approximately $4.3 billion. Partners Daniel Peale, David Silverman and Nicolas Dumont led the Cooley team advising Core Scientific.

Read more

Related contacts

Daniel Peale
Partner, Washington, DC
David Silverman
Partner, New York
Eileen Marshall
Partner, Washington, DC
David Safren
Associate, Miami
Pengli Li
Associate, Boston
Todd Gluth
Partner, San Diego
Howard Morse
Senior Counsel, Washington, DC
Sharon Connaughton
Special Counsel, Washington, DC
David Walsh
Senior Counsel, Reston
Calvin Lee
Associate, New York
Christian Lee
Special Counsel, San Francisco

Related Practices & Industries

Finch Therapeutics – $128 Million IPO

April 8, 2021

Cooley advised Finch Therapeutics on its $127.5 million initial public offering of 7,500,000 shares of common stock. Finch Therapeutics, whose securities now trade on the Nasdaq Global Select Market under the symbol FNCH, is a clinical-stage microbiome therapeutics company. Partners Div Gupta and Ryan Sansom led the Cooley team.

Related contacts

Div Gupta
Partner, New York
Ryan Sansom
Partner, Boston
Courtney Thorne
Partner, London
Trey Reilly
Associate, New York
Michael Bruno
Associate, New York
Pengli Li
Associate, Boston

Related Practices & Industries

Advises Anchiano Therapeutics Ltd on its reverse-merger with Chemomab

February 26, 2021

Cooley advised Anchiano Therapeutics Ltd, a preclinical biopharmaceutical company developing targeted therapies to treat cancer in areas of significant clinical need, on its reverse-merger with Chemomab.

Related contacts

Mark Jones
Associate, London
Pengli Li
Associate, Boston

Related Practices & Industries

View more

Admissions and credentials

Massachusetts

New York